Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg

Trial Profile

Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jan 2017 Planned End Date changed from 1 Feb 2016 to 30 Mar 2019.
    • 30 Jan 2017 Planned primary completion date changed from 1 Feb 2015 to 30 Mar 2019.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top